Dendritic cells (DCs) can present tumoral antigens to T-cells and stimulate T-cell-mediated
anti-tumoral immune responses. In addition to uptaking, processing, and presenting tumoral …

Multiple myeloma (MM) is a common hematological malignancy that has fostered several
new therapeutic approaches to combat newly diagnosed or relapsed MM. While the field …

Background & Aims Chronic HBV is clinically categorized into 4 phases by a combination of
serum HBV DNA levels, HBeAg status and alanine aminotransferase (ALT): immunotolerant …

The treatment landscape of multiple myeloma (MM) has evolved considerably with the FDA-
approval of at least 15 drugs over the past two decades. Together with the use of autologous …

Background The aim of this trial was to investigate the addition of the anti-SLAMF7
monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) …

Chimeric antigen receptor-modified T cell (CAR-T) immunotherapy has revolutionised blood
cancer treatment. Parsing the genetic underpinnings of T cell quality and CAR-T efficacy is …

Simple Summary Defining the specificity and biological sequalae induced by receptors
differentiated expressed in multiple myeloma cells are critical for the development of …

N-linked glycosylation of proteins is one of the post-translational modifications (PTMs) that
shield tumor antigens from immune attack. Signaling lymphocytic activation molecule family …

Novel therapeutic drugs have dramatically improved the overall survival of patients with
multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a …

Competent T-cells with sufficient levels of fitness combat cancer formation and progression.
In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor …